HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Chronic Hepatitis D

Subscribe to New Research on Chronic Hepatitis D

INFLAMMATION of the LIVER in humans caused by HEPATITIS DELTA VIRUS in conjunction with HEPATITIS B VIRUS and lasting six months or more.

Also Known As:

Hepatitis D, Chronic; Chronic Delta Hepatitides; Delta Hepatitides, Chronic; Hepatitides, Chronic Delta; Hepatitis, Chronic Delta; Chronic Delta Hepatitis; Delta Hepatitis, Chronic

Networked: 138 relevant articles (23 outcomes, 26 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Infection
2.	Liver Diseases (Liver Disease)
3.	Fibrosis (Cirrhosis)
4.	Hepatitis D
5.	Viremia

Experts

1.	Yurdaydin, Cihan: 9 articles (12/2015 - 08/2002)
2.	Bozkaya, Hakan: 5 articles (12/2015 - 08/2002)
3.	Rizzetto, Mario: 5 articles (04/2015 - 09/2006)
4.	Idilman, Ramazan: 4 articles (12/2015 - 09/2012)
5.	Dalekos, George N: 4 articles (12/2015 - 01/2007)
6.	Zachou, Kalliopi: 4 articles (12/2015 - 01/2007)
7.	Huang, Yi-Hsiang: 4 articles (04/2009 - 03/2005)
8.	Wu, Jaw-Ching: 4 articles (04/2009 - 03/2005)
9.	Zeuzem, Stefan: 3 articles (12/2015 - 03/2010)
10.	Tabak, Fehmi: 3 articles (12/2015 - 04/2006)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Chronic Hepatitis D:

1.	InterferonsIBA 03/01/2015 - "In this study, we aimed to determine the efficacy of pegylated-interferon α 2a (Peg-IFN α 2a) and 2b (Peg IFN α 2b) in the treatment of patients infected with chronic delta hepatitis virus. " 09/01/2011 - "The aim of this study was to evaluate the efficacy of pegylated interferon (PEG-IFN) alfa-2b for short (one year) and long (two years) terms of treatment for chronic hepatitis D. " 10/01/1991 - "The results of this study, which has been interrupted at the 4th month, suggest that interferon therapy for chronic delta hepatitis has to be considered cautiously in young patients cured of pediatric malignancies. " 01/01/2013 - "To determine the efficacy of pegylated interferon-α (PEG-IFN-α) therapy for 24 months in chronic delta hepatitis (CDH). " 01/01/2013 - "Efficacy of pegylated interferon-α treatment for 24 months in chronic delta hepatitis and predictors of response."
2.	Interferon-alpha (Interferon Alfa)FDA Link 01/24/2007 - "Finally, recent studies using pegylated interferon-alpha have shown promising results for the treatment of chronic hepatitis D." 12/01/2004 - "Long-term outcome improvement in patients with chronic hepatitis D treated with interferon alpha." 01/01/1993 - "Italian trials of interferon alpha in chronic delta hepatitis." 01/01/2011 - "To evaluate the beneficial and harmful effects of interferon alpha for patients with chronic hepatitis D. " 01/01/2011 - "Interferon alpha for chronic hepatitis D."
3.	RNA (Ribonucleic Acid)IBA 04/01/2013 - "Development and assessment of a novel real-time PCR assay for quantitation of hepatitis D virus RNA to study viral kinetics in chronic hepatitis D." 12/01/1994 - "These results suggest that the determination of HDV-RNA by the hybridization method can be of great value for the diagnosis and monitoring of chronic delta hepatitis." 12/01/1994 - "HDV RNA was detected in 26 of 28 patients with chronic delta hepatitis using the polymerase chain reaction. " 12/01/1994 - "We studied 28 patients with chronic delta hepatitis for the presence of hepatitis delta virus (HDV) RNA in serum. " 12/01/1994 - "Hepatitis delta virus RNA in serum of patients with chronic delta hepatitis."
4.	Ribavirin (Virazole)FDA LinkGeneric 03/01/2005 - "In this study, the efficacy of IFN-alpha and ribavirin combination therapy for chronic hepatitis D was investigated. " 03/01/2005 - "In conclusion, combination treatment of IFN-alpha and ribavirin for chronic hepatitis D is not able to induce virological responses at a sufficient rate, despite its partial effectiveness in improving biochemical responses, and is not superior to IFN-alpha monotherapy." 03/01/2005 - "Nineteen patients (15 males; mean age +/- standard deviation, 36.8 +/- 12.8 years) with chronic hepatitis D who were treated with IFN-alpha2b (10 million U, three times/week, subcutaneously) and ribavirin (1,000 to 1,200 mg/day, orally) for 24 months were studied. " 06/01/1994 - "To assess whether therapy with Ribavirin may affect the course of chronic delta hepatitis, nine Italian patients with this disease received the drug orally at a dosage of 15 mg/kg daily for 16 weeks. " 06/01/1994 - "Ribavirin treatment for chronic hepatitis D: a pilot study."
5.	Lamivudine (3TC)FDA Link 04/01/2006 - "The aim of this study was to test the efficacy of IFN-alpha 2b and lamivudine combination treatment in comparison to IFN-alpha 2b alone in patients with chronic delta hepatitis. " 08/01/2005 - "Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study." 08/01/1999 - "Lamivudine for chronic delta hepatitis." 08/01/1999 - "We have evaluated lamivudine (3-thiacytidine), an oral nucleoside analogue with marked effects against hepatitis B, as therapy in 5 patients with chronic hepatitis D. " 04/01/2006 - "Efficacy of interferon alpha-2b and lamivudine combination treatment in comparison to interferon alpha-2b alone in chronic delta hepatitis: a randomized trial."
6.	Recombinant Interferon Type IIBA 11/01/1989 - "For this reason, the aim of the present study was to determine the efficacy of recombinant interferon alpha (rIFN-alpha) treatment of chronic delta hepatitis, by giving high doses of rIFN-alpha 2c during a prolonged period. " 06/01/1991 - "To determine whether long-term therapy with recombinant interferon-alpha can improve the course of chronic delta hepatitis, 61 Italian patients with this disease were randomly assigned to receive either interferon-alpha-2b three times a week (5 MU/m2 for 4 mo and then 3 MU/m2 for another 8 mo) or no treatment. " 01/01/1991 - "Long term treatment of chronic delta hepatitis with alpha recombinant interferon."
7.	entecavir FDA Link 09/01/2012 - "The aim of this study was to investigate the efficacy of entecavir in chronic hepatitis D (CHD). " 09/01/2012 - "Entecavir treatment of chronic hepatitis D."
8.	thymic humoral factor gamma 2IBA 04/01/2002 - "To evaluate tolerability and efficacy of thymic humoral factor-gamma 2 in chronic hepatitis D. " 04/01/2002 - "Intramuscular thymic humoral factor-gamma 2, 40 microg, was given for 15 consecutive days and twice weekly for 22 additional weeks to adult patients with chronic hepatitis D virus hepatitis. " 04/01/2002 - "Treatment of chronic hepatitis D with thymus-derived polypeptide thymic humoral factor-gamma 2: a pilot study." 04/01/2002 - "At the doses given, thymic humoral factor-gamma 2 has been of limited efficacy A possible role of thymic humoral factor-gamma 2 in the treatment of chronic hepatitis D requires further dose-finding studies and/or combination with other antivirals."
9.	Carbon MonoxideIBA 01/01/2014 - "The mechanisms whereby HDV leads to accelerated liver disease in hepatitis B virus (HBV)/HDV co-infected patients and the histological characteristics of chronic hepatitis D (CHD) patients need further investigation. " 01/01/1997 - "Another model of virus-induced autoimmunity in man is chronic hepatitis D which always requires co-infection with hepatitis B. " 03/01/2013 - "Chronic Delta/hepatitis B viral co-infection runs a more severe course than that resulting from chronic hepatitis B virus infection alone, with progression to cirrhosis being more likely and more rapid. " 12/02/2005 - "Efficacy of pegylated interferon alpha-2b for the treatment of chronic delta hepatitis in a patient co-infected with HIV."
10.	Interferon Alfa-2a (Interferon Alfa 2a)FDA Link 01/13/1994 - "Treatment of chronic hepatitis D with interferon alfa-2a." 01/13/1994 - "To evaluate the efficacy of treatment with interferon, we studied 42 patients with chronic hepatitis D who were randomly assigned to receive either 9 million or 3 million units of recombinant interferon alfa-2a (three times a week for 48 weeks) or no treatment. " 01/13/1994 - "In about half the patients with chronic hepatitis D treated with high doses of interferon alfa-2a (9 million units three times a week for 48 weeks), the serum alanine aminotransferase level becomes normal, HDV RNA becomes undetectable in serum, and there is histologic improvement. "

Therapies and Procedures

1.	Transplants (Transplant) 08/01/2002 - "Since successful treatment of a case of post-transplant delta hepatitis with the nucleoside analogue famciclovir had been reported, a pilot study was undertaken to evaluate the use of famciclovir in the treatment of chronic delta hepatitis. " 07/01/1990 - "We have investigated the usefulness of serum hepatitis delta virus (HDV) RNA detection using a slot hybridization analysis of serum samples from ten patients with acute hepatitis and delta markers (group I), from 28 patients with chronic delta hepatitis (group II) and from seven liver graft recipients with hepatitis B virus (HBV) and HDV related cirrhosis or fulminant hepatitis (group III). "
2.	Liver Transplantation 02/01/1995 - "Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis." 03/01/1998 - "The kinetics of the immunoglobulin (Ig) M type antibody to the hepatitis D virus (IgM anti-HD) were investigated in hepatitis B surface antigen (HBsAg) carriers with chronic hepatitis D treated with interferon (IFN) and in patients with terminal hepatitis delta virus (HDV) cirrhosis who underwent liver transplantation. "
3.	Aftercare (After-Treatment) 11/01/2007 - "High dose interferon treatment for 1 year is the only established treatment for chronic hepatitis D, but it is associated with a high relapse rate after treatment discontinuation. " 03/01/1992 - "Seven carriers of the Hepatitis B surface antigen who had acquired a form of chronic hepatitis D in the recent past were treated with lymphoblastoid alpha interferon (IFN) (10 MU three times weekly for 4 months, 6 MU three times weekly for other 8 months, with a 12 month follow-up after treatment). "